Yourgene wins Australian approval for chemotherapy toxicity screening assay

pharmafile.com | November 17, 2026 | News story | |  Hospital Management, Oncology, Pharmacy, approvals, chemotherapy, diagnostic testing 

Yourgene Health has secured Australian regulatory approval for its Insight DPYD assay, enabling its use in clinical diagnostic testing to identify cancer patients at increased risk of severe toxicity from 5-fluorouracil (5-FU), a fluoropyrimidine chemotherapy drug.

Therapeutic Goods Administration (TGA) approval allows Southern Cross Diagnostics, also part of the Novacyt Group, to market and supply the in-vitro diagnostic (IVD) assay in Australia. Southern Cross Diagnostics holds the relevant Australian Register of Therapeutic Goods inclusion, while Yourgene manufactures the product.

The assay detects 19 clinically relevant variants in the DPYD gene, which can help identify patients at increased risk of severe or potentially fatal adverse reactions to 5-fluorouracil (5-FU). The results provide information to support clinical decisions about chemotherapy treatment and patient management.

Advertisement

Approval extends the assay’s commercial use beyond research applications. This has followed its launch as a research-use-only product in May 2026 and achievement of certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) in September.

Yourgene said the assay is the first CE-marked DPYD test certified under IVDR to include all current Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology and the National Comprehensive Cancer Network.

Novacyt chief executive officer Lyn Rees said the Australian approval would extend access to the company’s pharmacogenetic testing technology and support growth in its clinical genetics business.

Pic: NCI

Related Content

MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients

The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in …

lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been …

The Gateway to Local Adoption Series

Latest content